Lunit vs Viz.ai (2026)
Two imaging AI companies on different clocks. Lunit works cancer detection on mammography, tomosynthesis and chest radiographs, where the failure is a missed lesion found months later and the evidence that matters comes from screening. Its strongest study, ScreenTrustCAD, followed 55,581 women in Swedish screening and found AI with one radiologist non inferior to two radiologists. Viz.ai works acute triage and notification, where the failure is a delayed intervention measured in minutes, and its product mobilizes the treating team. A health system may well run both in different departments. If screening is the program, start with Lunit. If time to treatment in stroke is, start with Viz.ai.
- Screening evidence from a prospective study: ScreenTrustCAD, 55,581 women in Sweden, found AI with one radiologist non inferior to two radiologists.
- A breast cancer platform: INSIGHT for mammography and tomosynthesis sits alongside Lunit International's density, risk and quality products, formerly Volpara.
- Subgroup results exist: an Emory led evaluation with Lunit coauthors reports INSIGHT DBT performance by patient subgroup.
- Coordination is the constraint: Viz One pairs detection with automatic alerts and team messaging on clinicians' phones.
- Evidence on care delivery: a post hoc analysis of a multicenter prospective randomized trial reported door to groin times 11 minutes shorter.
- Security terms published: SOC 2 Type II, ISO 27001 and ISO 42001 on the Trust Center, with business associate terms in the subscription privacy policy.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Lunit and Viz.ai are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Lunit is a cancer focused medical AI company founded in 2013, headquartered in Seoul and listed on KOSDAQ. Its radiology line is Lunit INSIGHT: MMG for 2D mammography (FDA cleared 2021), DBT for tomosynthesis (cleared 2023) and CXR for chest X-ray (CXR Triage cleared 2021).
Source: AI Health Index, September 2026
AI powered care coordination platform, Viz One, that pairs detection algorithms on imaging and ECG with automatic alerts and team messaging on clinicians' phones. It began in stroke: its large vessel occlusion product, ContaCT, received FDA's De Novo authorization in 2018 (DEN170073), which created the regulatory category for imaging triage and notification software.
Source: AI Health Index, September 2026
Questions buyers ask
How do Lunit and Viz.ai work with the EHR?
Lunit embeds its algorithms in imaging hardware and viewers through equipment and technology partners, more than 100 by its count, and also delivers through the cloud, so a customer can acquire the AI as part of a scanner or viewer purchase rather than as a separate integration project.
With Viz.ai, the platform receives DICOM studies from scanners and PACS, and the De Novo summary describes the notification path to the mobile app with the images attached. The app is the working surface for neurologists, interventionalists and stroke teams across hospital networks. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How are Lunit and Viz.ai priced and sold?
Lunit sells INSIGHT and its breast platform direct and through imaging equipment and viewer partners, so the software can arrive inside or alongside a scanner or viewer purchase.
For Viz.ai, the website sets out how the product is sold: Viz One is an enterprise platform with therapeutic suites (neuro, vascular, cardio, pulmonary, trauma, radiology, oncology) and pilot programs, and the route in is a contact form. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How do Lunit and Viz.ai handle patient data?
With Lunit, the INSIGHT MMG FAQ says images from commercial sites are retained only for the duration of processing and are not used for retraining, that the models do not learn in real time, and that training data is biopsy proven material sourced through formal collaboration agreements.
The customer's contract sets how long Viz.ai keeps customer data. Usage data (which studies and alerts a clinician opened, response times) is de-identified to the HIPAA standard at 45 CFR 164.514 before it is used to improve services, build new products or conduct research. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
What evidence is published for Lunit and Viz.ai?
An independent external evaluation in JAMA Oncology (Salim and colleagues, 2020) compared three commercial algorithms on a retrospective Swedish screening cohort, and Lunit's had the highest accuracy.
With Viz.ai, a post hoc analysis of a multicenter, prospective, randomized trial of Viz LVO, led at UTHealth Houston, reported an 11 minute reduction in door to groin time across all centers. A parallel cohort of acute stroke consults at 166 facilities in 17 states compared AI and non AI sites. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
In the US, Lunit INSIGHT MMG is cleared as an adjunct viewed after the radiologist's initial read. Screening and acute triage are judged differently: a screening product on positive predictive value at your prevalence, an acute product on time to treatment. Site and publication counts are the companies' own, and Viz.ai sells some modules as pilot programs, which are not clearances.